PA
TAK icon

Probity Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Probity Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$748K Buy
46,692
+3,169
+7% +$52.4K 0.11% 125
2026
Q1 		$806K Buy
43,523
+90
+0.2% +$1.58K 0.13% 117
2025
Q4 		$677K Buy
43,433
+497
+1% +$7.11K 0.11% 122
2025
Q3 		$629K Buy
42,936
+1,608
+4% +$23.9K 0.1% 132
2025
Q2 		$639K Buy
41,328
+2,377
+6% +$35.1K 0.11% 129
2025
Q1 		$579K Sell
38,951
-4,344
-10% -$60.9K 0.11% 133
2024
Q4 		$573K Sell
43,295
-1
-0% -$14 0.11% 127
2024
Q3 		$616K Buy
43,296
+3,661
+9% +$51.9K 0.12% 130
2024
Q2 		$513K Buy
39,635
+14,856
+60% +$197K 0.11% 141
2024
Q1 		$344K Buy
24,779
+3,001
+14% +$43.6K 0.07% 176
2023
Q4 		$311K Buy
21,778
+4,290
+25% +$60.9K 0.07% 178
2023
Q3 		$271K Buy
17,488
+2,853
+19% +$44.2K 0.06% 162
2023
Q2 		$230K Buy
+14,635
New +$240K 0.05% 175
2022
Q4 		$196K Buy
12,548
+455
+4% +$6.36K 0.04% 179
2022
Q3 		$157K Buy
+12,093
New +$168K 0.04% 169

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Probity Advisors's TAK Position: Q2 2026 in Review

Probity Advisors increased its Takeda Pharmaceutical (TAK) stake by 7.3% in Q2 2026, buying an estimated $52.4K and bringing the position to 46,692 shares worth $748K. The position accounts for 0.11% of the portfolio, ranked #125.

Probity Advisors first reported a position in TAK in Q3 2022 and has held it in 15 quarters since. The position peaked at $806K in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Probity Advisors held 46,692 shares of Takeda Pharmaceutical worth $748K as of Q2 2026.
  • Probity Advisors bought 3,169 Takeda Pharmaceutical shares in Q2 2026, an estimated $52.4K.
  • Takeda Pharmaceutical made up 0.11% of Probity Advisors's portfolio in Q2 2026, its #125 holding.
  • Probity Advisors first reported a position in Takeda Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
  • Probity Advisors's Takeda Pharmaceutical position peaked at $806K in Q1 2026.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Probity Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.